Healthy gut microbiota can be disrupted due to antibiotic treatment, intestinal inflammation, or changes in diet. Targeted restoration of the microbiota will require an understanding of how genomic diversity between closely related microbes influences their ability to drive beneficial functions. To address this, our laboratory will use a large collection of whole-genome sequenced isolates to understand how variation between closely related gut isolates alters their ability to prevent pathogen expansion and maintain homeostatic interactions with the mucosal immune system.Learn More
Keyword: Antibiotic resistance
We are interested in microbial enzymes involved in the steroid and aromatic compounds degradation. These enzymes are important for bioremediation of organic pollutants and are potential targets for development of antibiotics against tuberculosis. In collaboration with Dr. Ting Zhou at Agriculture Agri-food Canada, we are isolating and characterizing enzymes capable of detoxifying the mycotoxins, deoxynivalenol and patulin. These mycotoxins contaminate grains and fruit juices.Learn More
Dr. Cezar Khursigara's research focuses on understanding how bacterial pathogens respond to their environment to cause disease. They are particularly interested in factors involved in biofilm formation and chronic infection. His research group is taking a multidisciplinary approach to answer fundamental questions related to how bacteria form biofilms to cause persistent infections. By combining advanced systems biology and imaging techniques, his goal is to identify potential therapeutics that can target a broad spectrum of disease-causing bacteria.Learn More
We are interested in characterizing the mechanisms of pathogenesis, adaptation, and survival in fungal and bacterial microbes from a systems biology perspective through mass spectrometry-based quantitative proteomics. Specifically, research in the lab centres around the following areas:
1) Systems biology to elucidate microbial proteome dynamics and interactions;
2) Mechanistic characterization of pathogenic proteins; and
3) Mass spectrometry-based proteomics for drug discovery and repurposing.